129 related articles for article (PubMed ID: 37755519)
1. Regional differences in clear cell metastatic renal cell carcinoma patients across the USA.
Scheipner L; Tappero S; Piccinelli ML; Barletta F; Garcia CC; Incesu RB; Morra S; Baudo A; Tian Z; Saad F; Shariat SF; Terrone C; De Cobelli O; Briganti A; Chun FKH; Tilki D; Longo N; Carmignani L; Pichler M; Hutterer G; Ahyai S; Karakiewicz PI
World J Urol; 2023 Nov; 41(11):2991-3000. PubMed ID: 37755519
[TBL] [Abstract][Full Text] [Related]
2. Regional differences in penile cancer patient characteristics and treatment rates across the United States.
Scheipner L; Cano Garcia C; Barletta F; Incesu RB; Morra S; Baudo A; Assad A; Tian Z; Saad F; Shariat SF; Chun FKH; Briganti A; Tilki D; Longo N; Carmignani L; Leitsmann M; Ahyai S; Karakiewicz PI
Cancer Epidemiol; 2023 Oct; 86():102424. PubMed ID: 37506474
[TBL] [Abstract][Full Text] [Related]
3. Regional differences in metastatic urothelial carcinoma of the urinary bladder patients across the United States SEER registries.
Garcia CC; Tappero S; Piccinelli ML; Barletta F; Incesu RB; Morra S; Scheipner L; Baudo A; Tian Z; Saad F; Shariat SF; Carmignani L; Ahyai S; Longo N; Tilki D; Briganti A; De Cobelli O; Terrone C; Banek S; Kluth L; Chun FKH; Karakiewicz PI
Can Urol Assoc J; 2023 Aug; 17(12):E412-9. PubMed ID: 37787591
[TBL] [Abstract][Full Text] [Related]
4. Regional differences in upper tract urothelial carcinoma patients across the United States.
Morra S; Scheipner L; Baudo A; Jannello LMI; de Angelis M; Siech C; Goyal JA; Touma N; Tian Z; Saad F; Califano G; la Rocca R; Capece M; Shariat SF; Ahyai S; Carmignani L; de Cobelli O; Musi G; Briganti A; Chun FKH; Longo N; Karakiewicz PI
Urol Oncol; 2024 May; 42(5):162.e1-162.e10. PubMed ID: 38336499
[TBL] [Abstract][Full Text] [Related]
5. Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients.
Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Mistretta FA; Tian Z; Musi G; Montanari E; Soulières D; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
Eur Urol Focus; 2021 May; 7(3):598-607. PubMed ID: 32444303
[TBL] [Abstract][Full Text] [Related]
6. Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study.
Marchioni M; Bandini M; Preisser F; Tian Z; Kapoor A; Cindolo L; Primiceri G; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
Eur Urol Focus; 2019 May; 5(3):488-496. PubMed ID: 29229582
[TBL] [Abstract][Full Text] [Related]
7. Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma.
Marchioni M; Harmouch SS; Nazzani S; Bandini M; Preisser F; Tian Z; Kapoor A; Cindolo L; Briganti A; Shariat SF; Schips L; Karakiewicz PI
Cancer Epidemiol; 2018 Jun; 54():112-118. PubMed ID: 29715680
[TBL] [Abstract][Full Text] [Related]
8. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm.
Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Parodi S; Dell'Oglio P; Palumbo C; Briganti A; De Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
Eur Urol Focus; 2023 Sep; 9(5):742-750. PubMed ID: 36906483
[TBL] [Abstract][Full Text] [Related]
9. Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities.
Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Nazzani S; Tian Z; Musi G; Montanari E; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
Cancer Causes Control; 2020 Mar; 31(3):263-272. PubMed ID: 31993859
[TBL] [Abstract][Full Text] [Related]
10. Other-cause mortality and access to care in metastatic renal cell carcinoma according to race/ethnicity.
Sorce G; Hoeh B; Hohenhorst L; Panunzio A; Tappero S; Tian Z; Larcher A; Capitanio U; Tilki D; Terrone C; Chun FKH; Antonelli A; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
Urol Oncol; 2022 Nov; 40(11):493.e9-493.e16. PubMed ID: 35907705
[TBL] [Abstract][Full Text] [Related]
11. Differences in Survival of Clear Cell Metastatic Renal Cell Carcinoma According to Partial vs. Radical Cytoreductive Nephrectomy.
Cano Garcia C; Flammia RS; Piccinelli M; Panunzio A; Tappero S; Barletta F; Incesu RB; Law KW; Morra S; Tian Z; Saad F; Kapoor A; Shariat SF; Longo N; Tilki D; Briganti A; Terrone C; Antonelli A; De Cobelli O; Hoeh B; Kluth LA; Chun FKH; Karakiewicz PI
Clin Genitourin Cancer; 2024 Feb; 22(1):1-6. PubMed ID: 37344282
[TBL] [Abstract][Full Text] [Related]
12. Differences in overall survival between clear cell metastatic renal cell carcinoma patients versus population-based controls according to race/ethnicity in the United States.
Cano Garcia C; Nimer N; Piccinelli ML; Tappero S; Panunzio A; Barletta F; Incesu RB; Tian Z; Saad F; Kapoor A; Briganti A; Terrone C; Shariat SF; Tilki D; Antonelli A; De Cobelli O; Kluth LA; Becker A; Chun FKH; Karakiewicz PI
Ann Epidemiol; 2023 Mar; 79():65-70. PubMed ID: 36640918
[TBL] [Abstract][Full Text] [Related]
13. Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis.
Xiao WJ; Zhu Y; Dai B; Zhang HL; Ye DW
Int Braz J Urol; 2015; 41(2):288-95. PubMed ID: 26005970
[TBL] [Abstract][Full Text] [Related]
14. A Population Study to Identify Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Sarcomatoid Renal Cell Carcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database.
Ji B; Li D; Fu S; Zhang Z; Yang T; Wu Y; Zuo Y; Xu Z; Yu N
Med Sci Monit; 2020 Jun; 26():e921297. PubMed ID: 32516796
[TBL] [Abstract][Full Text] [Related]
15. A non-cancer-related survival benefit is associated with partial nephrectomy.
Sun M; Trinh QD; Bianchi M; Hansen J; Hanna N; Abdollah F; Shariat SF; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI
Eur Urol; 2012 Apr; 61(4):725-31. PubMed ID: 22172373
[TBL] [Abstract][Full Text] [Related]
16. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era.
Marchioni M; Bandini M; Pompe RS; Tian Z; Martel T; Kapoor A; Cindolo L; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
Int Urol Nephrol; 2017 Dec; 49(12):2143-2149. PubMed ID: 28932952
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC).
Aizer AA; Urun Y; McKay RR; Kibel AS; Nguyen PL; Choueiri TK
BJU Int; 2014 May; 113(5b):E67-74. PubMed ID: 24053727
[TBL] [Abstract][Full Text] [Related]
18. Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.
Jiang W; Shou J; Shi H; Wen L; Zhang H; Zheng S; Li C; Ma J
Technol Cancer Res Treat; 2021; 20():15330338211019507. PubMed ID: 34032149
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Treatment Intensification on Other-Cause Mortality in Clear-Cell Metastatic Renal Cell Carcinoma Patients.
Incesu RB; Barletta F; Garcia CC; Scheipner L; Morra S; Baudo A; Assad A; Tian Z; Saad F; Shariat SF; Carmignani L; Longo N; Ahyai S; Chun FKH; Briganti A; Tilki D; Graefen M; Karakiewicz PI
Clin Genitourin Cancer; 2024 Apr; 22(2):420-425. PubMed ID: 38307818
[TBL] [Abstract][Full Text] [Related]
20. Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era.
Culp SH; Karam JA; Wood CG
Urol Oncol; 2014 Jul; 32(5):561-8. PubMed ID: 24709415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
